The Royal Marsden NHS Foundation and Trust
Welcome,         Profile    Billing    Logout  
 6 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Banerji, Udai
CRUKD/17/009, NCT03486730 / 2016-004633-24: BT1718 in Patients with Advanced Solid Tumours.

Hourglass Jun 2022 - Dec 2022 : Updated data for solid tumors
Completed
1/2
72
Europe
BT1718
Cancer Research UK, Bicycle Therapeutics
Advanced Solid Tumours, Non-Small Cell Lung Cancer, Non-Small Cell Lung Sarcoma, Oesophageal Cancer
11/23
11/23
NCT01226316: Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1
285
Europe, Canada, Japan, US, RoW
AZD5363
AstraZeneca
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
04/19
12/24
FRAME, NCT03875820: Phase I Trial of Defactinib and VS-6766.

Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Sep 2020 - Sep 2020: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Checkmark Data from FRAME trial in combination with VS-6766 for solid tumors at AACR 2020
More
Active, not recruiting
1
87
Europe
VS-6766, RO5126766, CH5126766, Defactinib, VS-6063
Institute of Cancer Research, United Kingdom, Verastem, Inc.
NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
04/23
10/23
NCT05382936: Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors

Terminated
1
20
Europe
SL-901
Stemline Therapeutics, Inc.
Advanced Solid Tumor
05/23
05/23
DDU RAF/MEK, NCT02407509: Phase I Trial of VS-6766 Alone and in Combination With Everolimus

Recruiting
1
104
Europe
VS-6766, Everolimus
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom, Chugai Pharmaceutical, Verastem, Inc.
Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
05/24
05/24
ACT, NCT04021277: PS101-mediated With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

Terminated
1
11
Europe
20 uL/kg PS101, 40 uL/kg PS101, Ultrasound
EXACT Therapeutics AS
Solid Tumor, Colorectal Cancer
08/24
09/24
NXP900-101, NCT05873686: A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers

Recruiting
1
40
Europe, US
NXP900
Nuvectis Pharma, Inc.
Advanced Solid Tumor
01/25
04/25
NXP800-101, NCT05226507: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

Recruiting
1
61
Europe, US
NXP800
Nuvectis Pharma, Inc., European Network for Gynaecological Oncological Trial Groups, Gynecologic Oncology Group Foundation
Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
05/25
12/25
BYON3521.001, NCT05323045: A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Active, not recruiting
1
31
Europe
BYON3521
Byondis B.V.
Solid Tumor
07/24
07/24

Download Options